Kiniksa Pharmaceuticals International PLC (NAS:KNSA)
$ 22.35 0.74 (3.42%) Market Cap: 1.59 Bil Enterprise Value: 1.33 Bil PE Ratio: 203.18 PB Ratio: 3.66 GF Score: 62/100

Kiniksa Pharmaceuticals Ltd at Goldman Sachs Healthcare Conference Transcript

Jun 13, 2023 / 03:40PM GMT
Release Date Price: $16 (+2.24%)
Paul Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst

We'll continue with our next session. I'm Paul Choi, and I cover the small and mid-cap biotechnology sector here at Goldman Sachs. It's my pleasure to welcome the management team from Kiniksa. We're joined by, to my left, CEO, Sanj Patel. We also have Dr. John Paolini, CMO, and we have Ross Moat, with commercial.

What we'll do, as we have in prior sessions, is let Sanj get off with some high-level comments. We'll go into Q&A after that. If any audience members along the way have questions, please feel free to raise your hand, and we'll try and get a mic to you. Alternatively, if you're listening on the webcast, please feel free to e-mail us your questions, and I'll read them anonymously. But with that, I'll turn it over to Sanj for some opening comments.

Sanj K. Patel
Kiniksa Pharmaceuticals, Ltd. - CEO & Chairman of the Board

Thank you, Paul. Great to be here. Obviously, we've also got Eben Tessari here, who's our Chief Operating Officer; and Mark Ragosa, who's our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot